Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects

Diabetes Care

Volumn 25, Issue 8, 2002, Pages 1398-1404

  Elbrond, Bodil ^a   Jakobsen, Grethe ^a   Larsen, Soren ^a   Agerso, Henrik ^a   Jensen, Lisbeth Bjerring ^a   Rolan, Paul ^b   Sturis, Jeppe ^a   Hatorp, Vibeke ^a   Zdravkovic, Milan ^a  

^a NOVO NORDISK A S   (Denmark)

^b Medeval Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCOSE; INSULIN; LIRAGLUTIDE; PLACEBO; ANTIDIABETIC AGENT; DRUG DERIVATIVE; GLUCAGON LIKE PEPTIDE 1;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD GLUCOSE MONITORING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOSE CALCULATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; INSULIN BLOOD LEVEL; INTRAVENOUS GLUCOSE TOLERANCE TEST; MALE; NAUSEA; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; SINGLE DRUG DOSE; VOMITING; ADOLESCENT; BLOOD; MIDDLE AGED;

ADOLESCENT; ADULT; BLOOD GLUCOSE; DOUBLE-BLIND METHOD; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED;

EID: 0036676385     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.25.8.1398     Document Type: Article

References (28)

1. Kiefer TJ, Habener JF: The glucagon-like peptides. Endocr Rev 20:876-913, 1999
2. Gutniak MK, Linde B, Holst JJ, Efendic S: Subcutaneous injection of the incretin hormone GLP-1 abolishes postprandial glycaemia in NIDDM. Diabetes Care 17:1039-1044, 1994
3. Nauck MA, Wollschlāger D, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Willms B: Effects of subcutaneous GLP-1 [7-36 amide] in patients with NIDDM. Diabetologia 39:1546-1553, 1996
4. Nathan DM, Schreiber E, Fogel H, Mojsov S, Habener JF: Insulinotropic action of glucagonlike peptide-1-(7-37) in diabetic and nondiabetic subjects. Diabetes Care 15:270-276, 1992
5. Qualman C, Nauck M, Holst JJ, Ørskov C, Creutzfeldt W: Insulinotropic actions of intravenous glucagon-like-peptide [7-36 amide] in the fasting state in healthy subjects. Acta Diabetol 32:13-16, 1995
6. Toft-Nielsen MB, Madsbad S, Holst JJ: Continuos subcutaneous infusion of glucagon-like-peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care 22:1137-1143, 1999
7. Nauck MA, Kleine N, Ørskov C, Holst JJ, Willms B, Creutzfeldt W: Normalisation of fasting hyperglycaemia by exogenous GLP-1 [7-36 amide] in type 2 diabetic patients. Diabetologia 36:741-744, 1993
8. Kreymann B, Williams G, Ghatei MA, Bloom SR: Glucagon-like-peptide 1 7-36: a physiological incretin in man. Lancet 2:1300-1304, 1987
9. Ritzel R, Ørskov C, Holst JJ, Nauck MA: Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers: dose relationships. Diabetologia 38:720-725, 1995
10. Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ: Truncated GLP-1 (proglucagon 72-107 amide) inhibits gastric and pancreatic function in man. Dig Dis Sci 38:665-673, 1993
11. Näslund E, Gutniak MK, Skogar S, Rössner S, Hellström PM: GLP-1 increases the period of postprandial satiety and slows gastric emptying in obese humans. Am J Clin Nutr 68:525-530, 1998
12. Näslund E, Barkeling B, King N, Gutniak M, Blundell JE, Holst JJ, Rossner S, Hellstrom PM: Energy intake and appetite are suppressed by glucagon-like-peptide 1 (GLP-1) in obese men. Int J Obes Relat Metab Disord 23:304-311, 1999
13. Edvell A, Lindström P: Initiation of increased pancreatic islet growth in young normoglycaemic mice (Umeå +/?). Endocrinology 140:778-783, 1999
14. Kurtzhals P, Havelund S, Jonassen I, Kiehr B, Larsen UD, Ribel U, Markussen J: Albumin-binding of insulins acylated with fatty acids: characterization of the ligand protein-interaction and correlation between binding-affinity and timing of the insulin effect in-vivo. Biochem J 312:725-731, 1995
15. Markussen J, Havelund S, Kurtzhals P, Andersen AS, Halstrom J, Hasselager E, Larsen UD, Ribel U, Schaffer L, Vad K, Jonassen I: Soluble fatty-acid acylated insulins bind to albumin and show protracted action in pigs. Diabetologia 39:281-288, 1996
16. Chou JZ, Place GD, Waters DG, Kirkwood JA, Bowsher RR: A radioimmunoassay for LY315902, an analogue of glucagon-like insulinotropic peptide, and its application in the trial of canine pharmacokinetics. J Pharm Sci 86:768-773, 1997
17. Knudsen LB, Nielsen PF, Huusfeldt PO, Johansen NL, Madsen K, Pedersen FZ, Thogersen H, Wilken M, Agerso H: Potent derivatives of GLP-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem 43:1664-1669, 2000
18. Ribel U, Hvidt M, Larsen MO, Rolin B, Wilken M, Knudsen LB: Glucose lowering of the protracted GLP-1 derivative, NN2211, in the β-cell reduced minipig. J Diabetologia 43 (Suppl. 1):560, 2000
19. Sturis J, Jappe MB, Knudsen LB, Wilken M, Gjedst-Ed A, Primdahl S, Gotfredsen CF: The long acting GLP-1 derivative NN2211 markedly slows the development of diabetes in the male Zucker diabetic fatty rat (Abstract). Diabetes 49 (Suppl. 1):A228, 2000
20. Larsen MO, Rolin B, Wilken M, Carr RD, Knudsen LB: NN2211, a long acting derivative of GLP-1, lowers blood glucose in ob/ob and db/db mice (Abstract). Diabetes 49 (Suppl. 1):A1, 2000
21. Agerso H, Jensen LB, Elbrond B, Rolan P, Zdravkovic M: The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a novel long-acting GLP-1 derivative, following seven days daily treatment in healthy male subjects. Diabetologia 45:195-202, 2002
22. Juhl CB, Hollingdal M, Sturis J, Jacobsen G, Veldhuis J, Porksen N, Schmitz O: Bed-time administration of NN2211, a long-acting GLP-1 derivative, results in substantial reduction in fasting and post-prandial glycemia in type 2 patients. Diabetes 51:424-429, 2002
23. Gutzwiller JP, Drewe J, Göke B, Schmidt H, Rohrer B, Lareida J, Beglinger C: Glucagon-like-peptide promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol 276:R1541-R1544, 1999
24. Gutzwiller JP, Göke B, Drewe J, Hildebrand P, Ketterer S, Handschin D, Winterhalder R, Conen D, Beglinger C: Glucagon-like-peptide: a potent regulator of food intake in humans. Gut 44:81-86, 1999
25. Knudsen LB, Agersoe H, Huusfeldt PO, Nielsen PF, Wilken M: Derivatives of glucagon-like-peptide-1 suitable for once daily administration (Abstract). Diabetes 48 (Suppl. 1):A202, 1999
26. Larsen J, Hylleberg B, Ng K, Damsbo P: Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment. Diabetes Care 24:1416-1421, 2001
27. Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Orskov C, Ritzel R, Schmiegel WH: Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol 273:E981-E988, 1997
28. Drucker DJ: Minireview: the glucagon-like peptides. Endocrinology 142:521-527, 2001